Srilatha Edupuganti

Dr. Srilatha Edupuganti

Emory university school of medicine

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
PAPrabhu Arunachalam
Prabhu Arunachalam
FWFlorian Wimmers
Florian Wimmers
CMChris Ka Pun Mok
Chris Ka Pun Mok
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
MSMadeleine Scott
Madeleine Scott
BPBali Pulendran
Bali Pulendran
Immune profiling of COVID-19 patients: Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathewet al.present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalamet al.report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions.Science, this issue p.eabc8511, p.1210

26 June 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
PLPremkumar Lakshmanane
Premkumar Lakshmanane
BSBruno Segovia-Chumbez
Bruno Segovia-Chumbez
RJRamesh Jadi
Ramesh Jadi
DMDavid R. Martinez
David R. Martinez
RRRajendra Raut
Rajendra Raut
ASAravinda M. de Silva
Aravinda M. de Silva
The serum level of RBD-binding antibodies correlates with SARS-CoV-2 neutralization and can be used for population-level surveillance.

31 July 2025 in Science
Verified
Journal Article
Open access
JWJordan R. Willis
Jordan R. Willis
MPMadhu Prabhakaran
Madhu Prabhakaran
MMMichelle Muthui
Michelle Muthui
ANAnsuya Naidoo
Ansuya Naidoo
TSTroy Sincomb
Troy Sincomb
WSWilliam R Schief
William R Schief
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.

9 July 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
SRStephen C. De Rosa
Stephen C. De Rosa
SESrilatha Edupuganti
Srilatha Edupuganti
YHYunda Huang
Yunda Huang
XHXue Han
Xue Han
MEMarnie Elizaga
Marnie Elizaga
MMM. Juliana McElrath
M. Juliana McElrath
BACKGROUND: HVTN 098, a randomized, double-blind, placebo-controlled trial, evaluated the safety, tolerability, and immunogenicity of PENNVAX-GP HIV DNA vaccine, administered with or without plasmid IL-12 (pIL-12), via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, HIV-uninfected adults. The study tested whether PENNVAX-GP delivered via ID/EP at one-fifth the dose could elicit equivalent immune responses to delivery via IM/EP and whether inclusion of pIL-12 provided additional benefit. METHODS: Participants received DNA encoding HIV-1 env/gag/pol in 3 groups: 1.6 mg ID (ID no IL-12 group, n = 20), 1.6 mg ID + 0.4 mg pIL-12 (ID + IL-12 group, n = 30), 8 mg IM + 1 mg pIL-12 (IM + IL-12 group, n = 30), or placebo ( n = 9) via EP at 0, 1, 3, and 6 months. Results of cellular and humoral immunogenicity assessments are reported. RESULTS: Following vaccination, the frequency of responders (response rate) to any HIV protein based on CD4 + T cells expressing IFN-γ or IL-2 was 96% for both the ID + IL-12 and IM + IL-12 groups; CD8 + T cell response rates were 64% and 44%, respectively. For ID delivery, the inclusion of pIL-12 increased CD4 + T cell response rate from 56% to 96%. The frequency of responders was similar (≥90%) for IgG binding antibody to gp140 consensus Env across all groups, but the magnitude was higher in the ID + IL-12 group compared with the IM + IL-12 group. CONCLUSION: PENNVAX-GP DNA induced robust cellular and humoral immune responses, demonstrating that immunogenicity of DNA vaccines can be enhanced by EP route and inclusion of pIL-12. ID/EP was dose sparing, inducing equivalent, or in some aspects superior, immune responses compared with IM/EP. TRIAL REGISTRATION: ClinicalTrials.gov NCT02431767. FUNDING: This work was supported by National Institute of Allergy and Infectious Diseases (NIAID), U.S. Public Health Service grants, an HIV Vaccine Design and Development Team contract, Integrated Preclinical/Clinical AIDS Vaccine Development Program, and an NIH award.

3 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MRMohammed Ata Ur Rasheed
Mohammed Ata Ur Rasheed
CHCarole J. Hickman
Carole J. Hickman
MMMarcia McGrew
Marcia McGrew
SSSun Bae Sowers
Sun Bae Sowers
SMSara Mercader
Sara Mercader
SESrilatha Edupuganti
Srilatha Edupuganti
Significance: The live-attenuated mumps-measles-rubella (MMR) vaccine has been highly successful in the United States since its introduction 47 years ago. However, for the past decade, mumps outbreaks have been occurring among young adults who were vaccinated as children. Waning immunity has been proposed as a key contributing factor to mumps resurgence. In our sample (n= 71) of 18- to 23-year-old college students, the majority had detectable mumps IgG antibodies by enzyme-linked immunosorbent assay (ELISA) but the magnitude was lower than rubella. Neutralizing antibody titers were 6-fold lower to a circulating genotype G mumps strain versus the vaccine strain. Ten percent of our participants had no detectable memory B cells to mumps. Strategies are needed to improve immunity to the mumps vaccine.

5 September 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
WHWilliam O. Hahn
William O. Hahn
KPK. Rachael Parks
K. Rachael Parks
MSMingchao Shen
Mingchao Shen
GOGabriel Ozorowski
Gabriel Ozorowski
HJHolly Janes
Holly Janes
MMM. Juliana McElrath
M. Juliana McElrath
Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140 formulated with a novel TLR7/8 signaling adjuvant, 3M-052-AF/Alum, for safety, adjuvant dose-finding, and immunogenicity in a first-in-healthy adult (n = 17), randomized, and placebo-controlled trial (HVTN 137A). The vaccine regimen appeared safe. Robust, trimer-specific antibody, and B cell and CD4+ T cell responses emerged after vaccination. Five vaccinees developed serum autologous tier 2 nAbs (ID50 titer, 1:28-1:8647) after two to three doses targeting C3/V5 and/or V1/V2/V3 Env regions by electron microscopy and mutated pseudovirus-based neutralization analyses. Trimer-specific, B cell–derived monoclonal antibody activities confirmed these results and showed weak heterologous neutralization in the strongest responder. Our findings demonstrate the clinical utility of the 3M-052-AF/Alum adjuvant and support further improvements of trimer-based Env immunogens to focus responses on multiple broad nAb epitopes.